Skip to content

investigating the effect of Viola tablet on breast cancer-related fatigue

investigating the effect of Viola odorata L. tablet on breast cancer-related fatigue: Pilot study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220302054170N1
Enrollment
20
Registered
2022-03-13
Start date
2022-04-21
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Unspecified type of carcinoma in situ of breast

Interventions

Intervention 1: The aqueous extract is prepared by boiling for 10 minutes using water in a ratio of 1:10. The extract prepared in the oven is dried at a temperature of 100 degrees and the resulting po

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Women aged 18 to 70 years old Suffering from breast cancer During radiotherapy Hemoglobin at least 8 g / dl Hematocrit at least 30% SGOT level less than 3 times the upper limit of normal Bilirubin less than 2mg / dl Creatinine less than 2mg / dl normal TSH

Exclusion criteria

Exclusion criteria: Heart disease with unstable conditions Debilitating lung disease History of asthma History of allergies to Viola or any of the excipients in tablets Uncontrolled pain Severe infection Serious accompanying disease

Design outcomes

Primary

MeasureTime frame
Visual Analogue Fatigue Scale. Timepoint: In weeks 0 and 4. Method of measurement: Questionnaire and Visual scale.;Fatigue Severity Scale. Timepoint: In weeks 0 and 4. Method of measurement: Questionnaire and Visual scale.;The Cancer Fatigue Scale. Timepoint: In weeks 0 and 4. Method of measurement: Questionnaire and Visual scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoma Hajimehdipoor

Shahid Beheshti University of Medical Sciences

hajimehd@sbmu.ac.ir+98 21 8877 6168

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026